教室紹介

2011年業績集

受賞

  1. Yokoyama M, Fujii Y, Iimura Y, Saito K, Koga F, Masuda H, Kihara K. 【Best of Poster】A nomogram for predicting the development of chronic kidney disease within 2 years after radical nephrectomy in patients with renal cortical tumor. The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  2. 齋藤一隆． 【第18回日本泌尿器科学会賞】Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma．

学会発表

欧州泌尿器科学会（European Association of Urology annual congress）

  1. Araki S, Sakura M, Tatokoro M, Yoshida S, Yokoyama M, Saito K, Koga F, Masuda H, Fujii Y, Kawakami S, Kihara K. A single-dose administration of antibiotic prophylaxis in minimally invasive radical prostatectomy; a prospective study of 300 consecutive cases. The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  2. Kobayashi S, Yoshida S, Koga F, Ishii C, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Diffusion-Weighted Magnetic Resonance Imaging Reflects Clinical Aggressiveness of Bladder Cancer The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  3. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. Potential role of Hsp90 inhibitors to overcome chemoradiotherapy resistance associated with HER-2 and NFκB overexpression in muscle-invasive bladder cancer The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  4. Koga F, Yokoyama M, Ishioka J, Numao N, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Who are at high-risk for cancer death among muscle-invasive bladder cancer patients treated with chemoradiation-based bladder-sparing protocols? The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  5. Komai Y, Numao N, Yoshida S, Sakura M, Okada Y, Ishii C, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. High diagnostic ability of multi-parametric magnetic resonance imaging in detecting prostate cancers missed by transrectal 12-core biopsy The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  6. Masuda H, Kawakami S, Sakura M, Fujii Y, Koga F, Saito K, Numao N, Yoshida S, Komai Y, Okada Y, Ito M, Yonese J, Fukui I, Kihara K. Performance of free PSA better than total PSA for estimation of prostate volume in elderly men without prostate cancer The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  7. Numao N, Kawakami S, Sakura M, Komai Y, Yokoyama M, Okada Y, Koga F, Saito K, Masuda H, Fujii Y, Yamamoto S, Yonese J, Ishikawa Y, Fukui I, Kihara K. Patient selection for hemiablative focal therapy of prostate cancer based on extended 14- or 26-core biopsy The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  8. Saito K, Ito M, Kijima T, Numao N, Koga F, Masuda H, Fujii Y, Kawakami S, Urakami S, Yuasa T, Yamamoto S, Yonese J, Fukui I, Kihara K. Impact of C-reactive protein kinetics on survival of castration-resistant prostate cancer patients treated with docetaxel The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  9. Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Masuda H, Kihara K. Phase-II trial of combination treatment of interferon-alfa, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA) for metastatic renal cell carcinoma. The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

  10. Yokoyama M, Fujii Y, Iimura Y, Saito K, Koga F, Masuda H, Kihara K. Significant recovery of renal function following radical nephrectomy in Japanese patients: A retrospective longitudinal study The 26th Annual Congress of the European Association of Urology, Vienna, Austria, 2011/3/18-22

米国泌尿器科学会（annual meeting of the American Urological Association）

  1. Fujii Y, Sakura M, Saito K, Iimura Y, Yasuda Y, Koga F, Masuda H, Kawakami S, Yonese J, Fukui I, Kihara K. NOMOGRAM TO PREDICT MINIMAL-FAT ANGIOMYOLIPOMA AT NEPHRECTOMY FOR RENAL MASSES PRESUMED TO BE STAGE 1 RENAL CELL CARCINOMA: IMPACT OF SEX, AGE, AND TUMOR SIZE The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  2. Kagawa M, Yoshida S, Numao N, Komai Y, Sakura M, Okada Y, Koga F, Saito K, Masuda H, Fujii Y, Ishii C, Kawakami S, Kihara K. Can men with a normal digital rectal examination and with negative findings on pre-biopsy multi-parametric magnetic resonance imaging avoid immediate prostate biopsy? The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  3. Kijima T, Yoshida S, Tatokoro M, Araki S, Yokoyama M, Numao N, Okada Y, Saito K, Koga F, Masuda H, Fujii Y, Kihara K. Antibiotic prophylaxis is not necessary in minimally invasive surgery for renal and adrenal tumors: A prospective study of 301 consecutive patients The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  4. Kobayashi S, Yoshida S, Koga F, Ishii C, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Diffusion-Weighted magnetic resonance imaging reflects pathologic phenotypes of bladder cancer The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  5. Koga F, Totokoro M, Kijima T, Sakura M, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Sensititivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  6. Koga F, Yokoyama M, Ishioka J, Numao N, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiation in bladder-sparing protocol The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  7. Komai Y, Numao N, Yoshida S, Kawakami S, Ishii C, Sakura M, Okada Y, Koga F, Saito K, Masuda H, Fujii Y, Kihara K. Multi-parametric magnetic resonance imaging can detect prostate cancers missed by transrectal 12-core biopsy with high accuracy The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  8. Numao N, Kawakami S, Sakura M, Komai Y, Yokoyama M, Okada Y, Koga F, Saito K, Masuda H, Fujii Y, Yamamoto S, Yonese J, Ishikawa Y, Fukui I, Kihara K. Negative result in unilateral 13-core biopsy can predict the absence of significant cancer on the ipsilateral lobe with a high accuracy. Implications for hemiablative focal therapy. The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  9. Tanaka H, Yoshida S, Fujii Y, Ishii C, Koga F, Saito K, Masuda H, Kawakami S, Kihara K. Diffusion-Weighted Magnetic Resonance Imaging in Differentiation of Angiomyolipoma with Minimal Fat from Clear Cell Renal Cell Carcinoma The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  10. Yasuda Y, Saito K, Sukegawa G, Ito M, Kubo Y, Yano A, Kitsukawa S, Yuasa T, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  11. Yokoyama M, Fujii Y, Iimura Y, Saito K, Koga F, Masuda H, Kihara K. A nomogram for predicting the development of chronic kidney disease within 2 years after radical nephrectomy in patients with renal cortical tumor The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  12. Yoshida S, Kobayashi S, Koga F, Ishii C, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Diffusion-Weighted Magnetic Resonance Imaging Reflects Pathologic Phenotypes of Bladder Cancer The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

  13. Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. Hsp90 inhibitors potentially overcome chemoradiotherapy resistance associated with HER-2 and NFκB overexpression in muscle-invasive bladder cancer The 105th annual meeting of the American Urological Association, Washington DC, USA, 2011/5/14-19

米国臨床癌学会泌尿生殖器癌シンポジウム（American Society of Clinical Oncology, Genitourinary Cancers Symposium）

  1. Fujii Y, Saito K, Iimura Y, Yasuda Y, Koga F, Masuda H, Yonese J, Ishikawa Y, Fukui I, Kihara K. INCIDENCE OF BENIGN PATHOLOGIC LESIONS AT NEPHRECTOMY FOR RENAL MASSES PRESUMED TO BE STAGE 1 RENAL CELL CARCINOMA IN JAPANESE PATIENTS: IMPACT OF SEX, AGE AND TUMOR SIZE. The 2011 Genitourinary Cancers Symposium, Orland, USA, 2011/2/17-19

  2. Iimura Y, Saito K, Fujii Y, Ishioka J, Iwai A, Numao N, Okada Y, Koga F, Masuda H, Kihara K. Use of C-reactive protein to predict perinephric or renal sinus fat invasion in patients with clinical T1N0M0 renal cell carcinoma The 2011 Genitourinary Cancers Symposium, Orland, USA, 2011/2/17-19

  3. Iwai A, Koga F, Kawakami S, Fujii Y, Masuda H, Saito K, Kihara K. Does induction chemoradiothepy compromise subsequent radical cystectomy? A single-institutional comparative study of perioperative complications according to the Clavien-Dindo classification. The 2011 Genitourinary Cancers Symposium, Orland, USA, 2011/2/17-19

  4. Okada Y, Masuda H, Saito K, Iimura Y, Yokoyama M, Komai Y, Numao N, Koga F, Fujii Y, Kihara K. Surgical outcomes of gasless single port retroperitoneal radical nephrectomy for dialysis patients: A comparative analysis with non-dialysis patients. The 2011 Genitourinary Cancers Symposium, Orland, USA, 2011/2/17-19

  5. Saito K, Kihara K, Numao N, Masuda H, Kijima T, Tatokoro M, Koga F, Fujii Y, Hayashi K, Shibuya H. Initial experience of focal therapy for prostate cancer using I-125 seed implantation: Unilateral ablation for patients selected by extended biopsy and MRI findings. The 2011 Genitourinary Cancers Symposium, Orland, USA, 2011/2/17-19

  6. Sakura M, Kawakami S, Ishioka J, Fujii Y, Yamamoto S, Iwai A, Numao N, Saito K, Koga F, Masuda H, Kumagai J, Yonese J, Fukui I, Kihara K. A novel repeat biopsy nomogram based on three-dimensional extended biopsy The 2011 Genitourinary Cancers Symposium, Orland, USA, 2011/2/17-19

  7. Tatokoro M, Saito K, Fujii Y, Komai Y, Koga F, Masuda H, Kawakami S, Kihara K C-reactive protein kinetics superior to radiographic response as a surrogate endpoint for survival in patients with advanced renal cell carcinoma. The 2011 Genitourinary Cancers Symposium, Orland, USA, 2011/2/17-19

原著

  1. Hayasaka K, Koyama M, Fukui I. FDG PET imaging in a patient with primary seminoma of the prostate. Clin Nucl Med. 36: 593-594, 2011.PubMed

  2. Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, Yamamoto S,Yonese J, Fukui I, Ishikawa Y. Diverse Fusion Patterns and Heterogeneous　Clinicopathologic Features of Renal Cell Carcinoma With t(6;11) Translocation. Am J Surg Pathol. [Epub ahead of print]PubMed

  3. Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, Kitsukawa S, Urakami S, Yuasa T, Yamamoto S, Yonese J, Fukui I. Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel. Urology. 78: 1131-1135, 2011.PubMed

  4. Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, Sakura M, Kawakami S, Kihara K. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 41: 1373-1379, 2011. PubMed

  5. Kagawa M, Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kihara K. A case of metastatic testicular germ-cell tumor with rhabdomyosarcoma successfully treated with germ-cell tumor-oriented chemotherapy. Int Canc Conf J. 1: 58-62, 2011.

  6. Kihara K. Minimum incision endoscopic radical prostatectomy. Nihon Rinsho. 69: Suppl 5: 350-354, 2011.

  7. Kobayashi S, Koga F, Yoshida S, Masuda H, Ishii C, Tanaka H, Komai Y, Yokoyama M, Saito K, Fujii Y, Kawakami S, Kihara K. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol. 21: 2178-2186, 2011.PubMed

  8. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS one. 6: e27616, 2011.PubMed

  9. Komai Y, Fujii Y, Iimura Y, Tatokoro M, Saito K, Otsuka Y, Koga F, Arisawa C, Kawakami S, Okuno T, Tsujii T, Kageyama Y, Morimoto S, Toma T, Higashi Y, Fukui I, Kihara K. Young Age as Favorable Prognostic Factor for Cancer-specific Survival in Localized Renal Cell Carcinoma. Urology. 77: 842-7, 2011.PubMed

  10. Ono H, Taniguchi Y, Komai Y, Kawamoto M, Hayashi H, Gemma A. A case of Prostate carcinoma Discovered with Pulmonary Lymphangitis Carcinomatosa. J Med Cases. 2: 81-86, 2011.

  11. Sakura M, Kawakami S, Ishioka J, Fujii Y, Yamamoto S, Iwai A, Numao N, Saito K, Koga F, Masuda H, Kumagai J, Yonese J, Fukui I, Kihara K. A novel repeat biopsy nomogram based on three-dimensional extended biopsy. Urology. 77: 915-920. 2011.PubMed

  12. Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Matsuoka Y, Iimura Y, Masuda H, Kihara K. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 102: 137-143, 2011．PubMed

  13. Saito K, Winnall WR, Muir JA, Hedger MP. Regulation of Sertoli cell activin A and inhibin B by tumour necrosis factor α and interleukin 1α: Interaction with follicle-stimulating hormone/adenosine 3',5'-cyclic phosphate signaling. Mol Cell Endocrinol. 335: 195-203, 2011．PubMed

  14. Urakami S, Yonese J, Yamamoto S, Yuasa T, Kitsukawa S, Numao N, Kubo Y, Ito M,Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I. Outcome of antegrade radicalprostatectomy with intended wide resection in prostate cancer patients with a　preoperative serum PSA level >100 ng/ml. Urol Int. 87: 175-81, 2011.PubMed

  15. Yokoyama M, Fujii Y, Iimura Y, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Longitudinal change in renal function after radical nephrectomy in Japanese patients with renal cortical tumors. J Urol. 185:2066-2071, 2011.PubMed

  16. Yoshida S, Masuda H, Ishii C, Tanaka H, Fujii Y, Kawakami S, Kihara K. Usefulness of diffusion-weighted MRI in diagnosis of upper urinary tract cancer. AJR Am J Roentgenol. 196: 110-116, 2011．PubMed

  17. Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. Low-dose Hsp 90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 10:4291-4299, 2011.PubMed

  18. Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M,Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T. Clinical efficacy and prognostic factors for overall survival in Japanese　patients with metastatic renal cell cancer treated with sunitinib. BJU Int. 109: 1349-54, 2011.PubMed

  19. Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I. Biomarkers to predict　response to sunitinib therapy and prognosis in metastatic renal cell　cancer. Cancer Sci. 102: 1949-57, 2011.PubMed

  20. Yuasa T, Urakami S, Yamamoto S, Yonese J, Saito K, Takahashi S, Hatake K,Fukui I. Treatment outcome and prognostic factors in renal cell cancer patients　with bone metastasis. Clin Exp Metastasis. 28: 405-11, 2011.PubMed

  21. Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S,Hatake K, Inamura K, Ishikwa Y, Fukui I. Tumor size is a potential predictor of　response to tyrosine kinase inhibitors in renal cell cancer. Urology. 77: 831-5, 2011.PubMed

  22. 飯降直男，川堀健一，山口実菜，杉山美帆，足立淳一郎，三原正明，杉山徹，泉山肇，吉本貴宣，小林秀一郎，猪狩亨，藤井靖久，北川昌伸，木原和徳，平田結喜緒． 高血圧クリーゼの発症を契機に診断された褐色細胞腫を合併した神経線維腫症1型の1例． 高血圧. 18: 2066-2071, 2011．

  23. 影山幸雄、黄　鼎文、河野友亮、福井直隆、東四雄、吉田大作、斎藤吉弘、田部井敏夫． 当施設における限局性前立腺癌、密封小浅源永久挿入治療導入後4年間の成績． 埼玉県医学会雑誌. 46(1):187-192, 2011.

  24. 木島敏樹、藤井靖久、飯村康正、沼尾昇、岡田洋平、齋藤一隆、古賀文隆、増田均、川上理、木原和徳. 遅延CAB療法に対するPSA responseはエストロゲン療法、ドセタキセル療法後の非増悪生存期間、全生存期間を予測する． 泌尿器外科. 43: 1307-1309, 2011.

  25. 木原和徳． 【前立腺癌(第2版)-基礎・臨床研究のアップデート-】 臨床　前立腺癌の治療　外科治療　ミニマム創内視鏡下前立腺全摘除術(解説/特集) . 日本臨床. 増刊5 前立腺癌. 69: 350-354, 2011.

  26. 木原和徳． ミニマム創内視鏡下手術の現状2010～2011(解説)． 日本ミニマム創泌尿器内視鏡外科学会雑誌. 3( 1): 101-106, 2011.

  27. 酒井康之、川野圭三、井上雅晴、森本信二. 急性腹症として発症した膀胱自然破裂の1例. 茨城県農村医学会雑誌. 24：26-28, 2011．

  28. 高沢亮治、北山沙知、小林秀一郎、荒木沙織、早稲田悠馬、兵地信彦、辻井俊彦． 腎・尿管結石に対するｒ＆ｆ-TUL100件の治療成績． 泌尿器科紀要. 57：411-416,2011.

  29. 竹下英毅、森山真吾. TUR廃材を用いたディスポーザブルカテーテルクランプ―TURBT後抗癌剤即時単回注入での利用． 臨床泌尿器科. 65（3）：240-241，2011.

  30. 福島啓司、古賀文隆、田所　学、横山みなと、齋藤一隆、増田　均、藤井靖久、川上　理、木原和徳. 転移巣に対する低用量化学放射線療法を主体とする集学的治療が奏効した腎盂原発小細胞癌の1例. 日本泌尿器科学会雑誌. 102: 638-643, 2011.

総説

  1. Masuda H, Kihara K, Fujii Y, Koga F, Saito K, Sakura M, Okada Y, Kawakami S. Renal Cell Carcinoma in Dialysis Patients with End Stage Renal Disease: Focus on Surgery and Pathology Hemodialysis - Different Aspects. ISBN 978-953-307-315-6, Publisher: InTech． 2011.

  2. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol. 8: 659-66, 2011.

  3. 岡田洋平、増田　均、藤井靖久、齋藤一隆、古賀文隆、木原和徳． 肥満例におけるミニマム創内視鏡下根治的腎摘除における臓器摘出のための最小皮膚切開創長の術前予測(解説). 日本ミニマム創泌尿器内視鏡外科学会雑誌, 3(1): 125-128, 2011.

  4. 影山幸雄. 有効から有益へ！－ＰＳＡ検診の将来. 総合健診, 38(6): 76-84, 2011.

  5. 古賀文隆、木原和徳、齋藤一隆、増田　均、藤井靖久. ミニマム創内視鏡下無阻血腎部分切除. 日本ミニマム創泌尿器内視鏡外科学会雑誌, 3: 153-156, 2011.

  6. 古賀文隆、木原和徳、齋藤一隆、増田　均、藤井靖久、川上　理. ミニマム創内視鏡下腎尿管全摘除. 小切開・鏡視外科学会雑誌, 2: 113-116, 2011.

  7. 砂倉瑞明, 木原和徳． 【スタンダード透析療法】 合併症と管理基準、管理法　多嚢胞化萎縮腎と腎細胞癌. 腎と透析, 70(増刊): 307-310, 2011年5月．

  8. 竹下英毅、森山真吾、千葉浩司、野呂　彰．特集　こんなときどうする!?―泌尿器科手術のトラブル対処法．I尿路内視鏡手術■経尿道的膀胱腫瘍切除術（TURBT）．006膀胱頂部から突然“ボン”と爆発音がした．臨床泌尿器科, 65(4): 29-30, 2011年4月.

  9. 竹下英毅、森山真吾、千葉浩司、野呂　彰. 特集　こんなときどうする!?―泌尿器科手術のトラブル対処法．I尿路内視鏡手術■経尿道的膀胱腫瘍切除術（TURBT）．007腫瘍切除後に，それまで確認できなかった尿管口が現れた．臨床泌尿器科, 65( 4): 31-33, 2011年4月.

  10. 竹下英毅、森山真吾、千葉浩司、野呂　彰. 特集　こんなときどうする!?―泌尿器科手術のトラブル対処法．IV開腹手術■根治的腎摘除術．066右腎摘除後に右下腹部の違和感を訴えている. 臨床泌尿器科, 65(4): 187-188, 2011年4月.

  11. 竹下英毅、森山真吾、千葉浩司、野呂　彰. 特集　こんなときどうする!?―泌尿器科手術のトラブル対処法．IV開腹手術■腎尿管全摘除術．070尿管引き抜き法を行ったあと血圧が急に下がった.臨床泌尿器科, 65(4): 197-199, 2011年4月.

  12. 沼尾　昇、横山みなと、砂倉瑞明、木原和徳．AUA/EAU/ASCO-GU2011で示された前立腺癌の診断. 泌尿器外科, 24: 1595-1597, 2011.

  13. 藤井靖久，木原和徳，酒井康之，川上　理，増田　均，古賀文隆，齋藤一隆，山本真也，米瀬淳二，福井　巌．前立腺全摘術後の鼠径ヘルニア発症を防止する腹膜鞘状突起切断法：　ミニマム創内視鏡下手術への導入．日ミニ泌鏡外会誌, 3: 77-80, 2011．

  14. 藤井靖久，横山みなと，木原和徳．根治的腎摘除および腎部分切除後の長期腎機能．Japanese Journal of Endourology, 24: 214-220, 2011.

  15. 藤井靖久，砂倉瑞明，木島敏樹，木原和徳．ASCO/AUA/EAUで示された進行性前立腺癌の治療．泌尿器外科, 24: 1607-1612, 2011.

  16. 増田　均、木原和徳、古賀文隆、齋藤一隆、藤井靖久、川上　理. ミニマム創内視鏡下腎尿管全摘除. 日本ミニマム創内視鏡下外科学会雑誌, 3: 91-94, 2011.

  17. 増田　均、木原和徳、古賀文隆、齋藤一隆、藤井靖久、川上　理. 各種副腎腫瘍に対するミニマム創内視鏡下副腎摘除. 小切開・鏡視外科学会雑誌, 2: 117-122, 2011.

  18. 増田 均. 腎癌・膀胱がん　改訂第2版　第２章　膀胱がん　診断　1.膀胱がんの診断：総論. 最新医学・別冊　新しい診断と治療のABC 45(別冊)，最新医学社，東京，163-171，2011．

  19. 横山みなと、藤井靖久、木原和徳．腎癌の手術・腎機能に焦点をあてて：ミニマム創内視鏡下腎部分切除　腎機能の腎摘除との比較を中心に．泌尿器外科, 24: 587-591, 2011.

  20. 米瀬淳二. 腎癌の手術・腎機能に焦点をあてて　腎部分切除(開放手術)．泌尿器外科，24（4）： 581-585，2011．

  21. 米瀬淳二．尿路変更術 回腸導管造設術．泌尿器外科，24（2）： 155-159，2011．

  22. 米瀬淳二．【ハイリスク前立腺癌に対する手術治療戦略】 ハイリスク前立腺癌に対する恥骨後式前立腺全摘術．泌尿器外科，24（2）：155-159，2011．

著書

  1. 飯村康正、木原和徳． 尿閉． 臨床研修イラストレイテッド２基本手技[救急処置]　奈良信雄編　羊土社，東京, 164-166，2011．

  2. 影山幸雄. 膿尿・細菌尿. 緊急度・重症度からみた症状別看護過程＋病態関連図 井上智子・佐藤千史編　医学書院,東京, 903-909, 2011.

  3. 北原聡史. 排尿痛. 緊急度・重症度からみた症状別看護過程＋病態関連図 井上智子・佐藤千史編　医学書院,東京, 836-840, 2011.

  4. 木原和徳． ミニマム創内視鏡下副腎摘除. 原発性アルドステロン症診療マニュアル　改訂第２版．平田結喜緒、成瀬光栄編, 診断と治療社，東京， 135-137, 2011.

  5. 木原和徳． 導尿法、膀胱穿刺法、膀胱瘻造設術． 今日の治療指針—2011年版．　962，山口　徹、北原光夫、　福井次矢　総編集,　医学書院，東京, 2011.

  6. 古賀文隆、木原和徳． 第2章　膀胱がん　管理・治療　２．筋層浸潤がん　（1）膀胱温存療法． 「新しい診断と治療のABC 45 腎がん・膀胱がん　改訂第2版」，木原和徳　編，最新医学社，大阪． 187－194，2011．

  7. 古賀文隆、木原和徳/那須佳津美． 18．膀胱癌． 人体の構造と機能からみた病態生理ビジュアルマップ３佐藤千史／井上智子　編，医学書院，東京． 169－176，2011．

  8. 齋藤一隆、木原和徳. 腎腫瘍（腎細胞癌）. 人体の構造と機能からみた病態生理ビジュアルマップ3佐藤千史、井上智子編　医学書院, 東京, 153-159, 2011.

  9. 齋藤一隆. 基本診断・治療・予後因子. 新しい診断と治療のABC45「腎がん・膀胱がん」 木原和徳編　最新医学社, 東京, 50-59, 2011.

  10. 砂倉瑞明、木原和徳． 性器：男性． 臨床研修イラストレイテッド３　基本手技（診察と検査）.　奈良信雄編, 136-137, 羊土社, 東京, 2011.

  11. 藤井靖久． 膀胱がん　管理・治療 筋層非浸潤性がん(表在がん） 178-186, 2011.

  12. 藤井靖久、木原和徳、酒井康之、川上　理、増田　均、古賀文隆、齋藤一隆、山本真也、米瀬淳二、福井　巌． 前立腺全摘術後の鼠径ヘルニア発症を防止する腹膜鞘状突起切断法　ミニマム創内視鏡下手術への導入． 日本ミニマム創泌尿器内視鏡外科学会雑誌， 3（1）： 77-80，2011.

  13. 増田　均、木原和徳、古賀文隆、斉藤一隆、藤井靖久、川上　理. ミニマム創内視鏡下腎尿管全摘除. 日本ミニマム創内視鏡下外科学会雑誌, 3: 91-94, 2011．

  14. 増田　均、木原和徳. 51 多尿・頻尿． 緊急度・重症度からみた症状別看護過程＋病態関連図. 866-882, 井上智子、佐藤千史編，医学書院，東京， 2011．

  15. 増田　均、木原和徳. 尿失禁. 症状別看護過程.　883-887, 井上 智子、佐藤千史編, 医学書院, 東京, 2011.

  16. 横山みなと、藤井靖久、木原和徳. 根治的腎摘除：腎機能を含めて. 腎がん・膀胱がん（第2版）. 木原和徳編, 最新医学社, 東京, 60-68, 2011．

研究会主催

  1. 第4回日本ミニマム創内視鏡外科学会学術集会，東京，2011年12月17-18日．

研究助成

  1. 木島敏樹．科学研究費補助金：若手(B) 23791745　ビスホスホネートによる泌尿器癌の治療感受性の増大とその分子生物学的機序の解析．

  2. 古賀文隆．科学研究費補助金：若手 (B) 21791490　膀胱癌の浸潤能および化学放射線療法治療抵抗性獲得における p63 蛋白の役割の解析．

  3. 古賀文隆．科学研究費補助金：基盤 (C) 23501266　膀胱癌の転移／治療耐性における p63 蛋白の役割．

  4. 田所　学．科学研究費補助金：若手 (B) 23791744　尿路上皮癌幹細胞の同定および癌幹細胞をターゲットとした治療モデルの構築．